EN DE
Watch Glaukos Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Glaukos Corp (GKOS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Glaukos Corp stock $145, price $236, that is 38.4% below the price, quality 46 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

GC Glaukos Corp logo Thin data Nov 10, 2026

Glaukos Corp

GKOS · US
Very expensive, weak quality

Our calculation puts a fair price 38% below what the stock costs today.

Low debt
Positive coverage
Revenue last quarter +58% vs. a year ago.
Quality 46/100
Expensive Growth (revenue 5y +17.7 %/yr in USD)
Insiders sold $35.1M (6M)
Fair value $145.49 · Strongly overvalued
Loss-making · -24.6% net margin (TTM)
Negative free cash flow
Trails peers (1/11)
Narrow moat 17/100 · thin data
Thin data
Estimate
Watch Glaukos Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$246.70 $34.86 Fair Value $145.49 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $34.86 – $246.70 · fair‑value band $109.12 – $181.87 · the $236.19 price screens above the $145.49 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Glaukos in your weekly email

Every Wednesday you see whether Glaukos is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.

Show moreShow less

It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor.

The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases.

It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors.

The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Stock analysis

Glaukos Corp (GKOS) currently trades at $236.19, while our estimate is $145.49, 38% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $109.12 (bear) to $181.87 (bull), the price of $236.19 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Glaukos Corp reported revenue of $507M in FY2025 versus $294M in FY2021, a compound +14.6%/yr. Reported net income was −$188M in FY2025.

Key figures

Market cap $13.8B Large · P/S ratio 21.2 · EPS (TTM) $−2.95 · Net margin −24.6% · Return on equity −22.8% · Return on assets (EBIT) −9.3% (5-year average) · Operating margin 0.4% · Revenue (TTM) $690M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).

What moves the price

The share trades about 4% below its 52-week high and 167% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −38%, GKOS screens richer than that median.

Fair Value

Bear $109.12 Fair Value $145.49 Bull $181.87
Price $236.19 · Downside -38.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 23
How much profit the company makes from its sales and capital
Quality Growth 74
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 78
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 94
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 97
Distance to the 52-week high, does not count
New shares 37
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 5 officers or directors sold shares worth $35.1M and none bought.

  • SaleGilbert H KlimanDirector5× since Dec 9, 2025: 20,000 shares, avg. $151.13$3.0MNov 4, 2026
  • SaleTomas NavratilCHIEF DEVELOPMENT OFFICER9× since Mar 16, 2026: 68,156 shares, avg. $212.65$14.5MOct 30, 2026
  • SaleJoseph E GilliamPRESIDENT & COO5× since Nov 18, 2025: 113,913 shares, avg. $151.31$17.2MAug 11, 2026
  • SaleAlex R. ThurmanSVP & CHIEF FINANCIAL OFFICER9× since Nov 25, 2025: 64,972 shares, avg. $156.61$10.2MAug 7, 202610b5-1 plan
  • SaleLeana WenDirector2× since May 1, 2026: 2,225 shares, avg. $149.08$331,701Jul 31, 2026
  • SaleAimee S WeisnerDirector15,000 shares at $117.38$1.8MFeb 19, 2026
  • SaleMarc StapleyDirector15,000 shares at $127.71$1.9MJan 22, 202610b5-1 plan
  • SaleThomas William BurnsCHAIRMAN & CEO, Director275,000 shares at $115.00$31.6MJan 16, 202610b5-1 plan

Plus 21 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Start year 2020 (pandemic). Over 10 years: +21.6% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+50.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−54.9% (2020) → −17.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GKOS screens overvalued: fair value 38% below the price. Compare with Abbott Laboratories, →

Recent news

News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Glaukos Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 46 · Below median
Fair Value upside −38.4% · Bottom 25%
Profitability
Return on assets −21.0% · Below median
Net margin (12 months) −24.6% · Bottom 25%
Operating margin (12 months) 0.4% · Below median
Growth and dividend
Revenue growth (quarter YoY) 58.0% · Top 25%
Balance sheet
Debt / equity 0.43× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 21.03× · Priciest 25%
P/S (12 months) 19.99× · Priciest 25%
PEG 1.64× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)100 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)78 · sector 97
DIVIDEND (yield)0 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs GKOS
DexCom, Inc DXCM $79.92 $89.18 +12% vs GKOS
Stryker Corporation SYK $324.29 $358.30 +10% vs GKOS
STERIS plc STE $257.12 $279.53 +9% vs GKOS
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs GKOS
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs GKOS
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs GKOS
Abbott Laboratories, ABT $110.46 $75.28 −32% vs GKOS
Medtronic plc MDT $101.59 $65.61 −35% vs GKOS
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs GKOS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Glaukos Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Glaukos Corp Fair Value". https://www.fairvalue-calculator.com/stock/GKOS

Frequently asked questions

Is Glaukos Corp (GKOS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $145.49 versus a price of $236.19, about 38% lower (overvalued).
What is the fair value of GKOS?
Our estimate for Glaukos Corp is $145.49 (as of Nov 10, 2026), built from audited fundamentals. The current price: $236.19.
What is the quality score of GKOS?
Glaukos Corp has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Glaukos Corp (GKOS)?
Our calculated price target is the estimate of $145.49 (as of Nov 10, 2026). Cautious scenario $109.12, optimistic scenario $181.87. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Glaukos Corp stock forecast for 2026?
Our estimate puts fair value at $145.49, about 38% lower versus a price of $236.19 (overvalued). Cautious scenario $109.12, optimistic scenario $181.87. The calculation is refreshed regularly with new filings.
What is the revenue of Glaukos Corp (GKOS)?
Glaukos Corp reported trailing-twelve-month revenue of about $690M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Glaukos Corp (GKOS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Glaukos Corp it is $145.49 per share (as of Nov 10, 2026), against a price of $236.19.
Is Glaukos Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, GKOS trades above its calculated fair value: price $236.19, fair value $145.49, a gap of about −38% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GKOS?
No. The price is what the market pays today ($236.19); the fair value is what the company's own numbers justify ($145.49). For Glaukos Corp the two are $90.70 per share apart. That gap is exactly why we show both numbers side by side.
How much is Glaukos Corp worth?
The market values Glaukos Corp at about $13.8B (market capitalisation, as of Nov 10, 2026). Per share that is $236.19; our models calculate a fair value of $145.49 per share.
What do the bullish and bearish scenarios say about GKOS?
Our models span a range for Glaukos Corp: cautious scenario $109.12, base $145.49, optimistic $181.87 per share (as of Nov 10, 2026, price $236.19). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of GKOS?
The PEG ratio of Glaukos Corp is 1.64 (P/E divided by earnings growth, as of Nov 10, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Glaukos Corp (GKOS)?
Balance-sheet figures for Glaukos Corp (as of Nov 10, 2026): return on equity −22.8%, debt of 0.43 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is GKOS from its 52-week high?
Glaukos Corp trades at $236.19, about 4% below its 52-week high of $246.70 and 167% above the low of $88.35 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $145.49 is for.
Which stocks are comparable to Glaukos Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Glaukos Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $236.19, calculated fair value $145.49 (−38%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Glaukos Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Glaukos Corp (GKOS)?
The closing price on Nov 10, 2026 was $236.19. Our estimate is $145.49, about 38% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Glaukos Corp right now?
The price sits above even our optimistic bull case ($181.87). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Glaukos Corp

How large is the market capitalisation of Glaukos Corp (GKOS)?
The market capitalisation of Glaukos Corp is $13.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Glaukos Corp (GKOS)?
The price-to-sales ratio of Glaukos Corp is 21.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Glaukos Corp (GKOS)?
Earnings per share at Glaukos Corp are $−2.95. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Glaukos Corp (GKOS)?
The net margin of Glaukos Corp is −24.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Glaukos Corp (GKOS)?
The return on equity (ROE) of Glaukos Corp is −22.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Glaukos Corp (GKOS)?
On an EBIT basis the return on assets of Glaukos Corp is −9.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Glaukos Corp (GKOS)?
The operating margin of Glaukos Corp is 0.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Glaukos Corp (GKOS)?
Revenue at Glaukos Corp is growing +58.0% versus a year earlier (3y avg +21.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Glaukos Corp (GKOS)?
Earnings per share at Glaukos Corp are growing +19.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Glaukos Corp (GKOS) generate?
The free cash flow of Glaukos Corp is −$54.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Glaukos Corp (GKOS) carry?
The net debt of Glaukos Corp is $48.8M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Glaukos Corp in the live analysis

One click puts Glaukos Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.